- Bright Minds Biosciences (DRUG) has dosed the first patient in a Phase I trial for its lead product, BMB-101 to treat Dravet Epilepsy Syndrome
- BMB-101 exhibits the potential to be the best-in-class drug and has demonstrated a significant reduction in both the number and intensity of epileptic seizures
- The Phase I trial is being conducted in Adelaide, Australia, by CMAX Clinical Research, a clinical trial centre specializing in a range of early-phase trials and first-time in-human studies
- Bright Minds Biosciences Inc. (DRUG) is down 20.82 per cent, trading at $2.32 per share as of 1:20 pm ET
Bright Minds Biosciences (DRUG) has dosed the first patient in a Phase I trial for its lead product, BMB-101 to treat Dravet Syndrome.
The Phase I trial is being conducted in Adelaide, Australia, by CMAX Clinical Research, a clinical trial centre specializing in a range of early-phase trials and first-time in-human studies.
BMB-101 is a next-generation, 5-HT2C selective and biased agonist that exhibits the potential to be the best-in-class drug. BMB-101 has demonstrated a significant reduction in both the number and intensity of epileptic seizures.
Dravet syndrome is an epilepsy syndrome that begins in infancy or early childhood and can include a spectrum of symptoms ranging from mild to severe.
The company’s Chief Medical Officer, Dr. Revati Shreeniwas explained that BMB-101 was designed to improve the safety profile relative to earlier medications in this class, offering the potential to deliver an improved therapeutic to address this disease.
“Based on the strength of BMB-101’s preclinical data and encouraging scientific rationale of 5-HT2C agonism in the treatment of Dravet Syndrome, we are enthusiastic to advance our lead product into clinical trials.”
Bright Minds’ Chief Executive Officer, Ian McDonald called this initial dosing in the first-in-human trial of BMB-101 a milestone for the company.
“After several years of discovery and early development of next-generation, best-in-class serotonergic investigational drugs, we are delighted to progress into human trials. We are hopeful that our efforts result in more efficacious and safer drugs for patients suffering from Dravet Syndrome, which remains an area of high unmet medical need.”
Bright Minds (DRUG) is a pre-clinical biosciences company focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain.
Bright Minds Biosciences Inc. (DRUG) is down 20.82 per cent, trading at $2.32 per share as of 1:20 pm ET.